•  
  •  
  •  
  •  

2026-05-27 13:47:22

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mayank Cattle Food Ltd launches Mayank Vita H Liquid
  • Morepen Labs Q4 Net Profit Rises 69%
  • AXISCADES Wins Order from DRDO's R & DE for Mobile Mast System
  • Senco Gold Ltd delivers highest ever top-line in FY26
  • Apeejay Surrendra Park Hotels Reports Q4 and Full-Year FY26 Financial Results

Keywords Selected:  GranulesIndia

Stock Report

  • Granules India Limited completes cGMP Audit at its Chantilly Site
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Granules India's Packaging Facility in US gets FDA EIR with No Action Indicated Status
  • Granules India Ltd consolidated Q3FY26 PAT climbs to Rs. 150.21 crores
  • Granules Pharmaceuticals Inc. receives FDA tentative approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Granules India Ltd receives official 2025 CDP rating
  • Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations
  • Granules India Strengthens R&D Leadership with Two New Centres of Excellence at IIT Hyderabad's Technology Research Park
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • Granules India earns Gold Rating in First-Ever Corporate-Level EcoVadis Assessment Ranks in the Top 5% Globally Across All Industries
  • Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
  • Granules India enters the high growing peptide segment and CDMO business by acquiring Senn Chemicals AG
  • Granules India Ltd posts consolidated PAT of Rs. 117.60 crores in Q3 FY2025
  • Granules India Limited announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.
  • Granules' Net Zero Commitment Validated and Approved by Science Based Targets Initiative
  • Granules India Ltd posts consolidated PAT of Rs. 97.23 crores in Q2 FY2025
  • Granules India Ltd announces ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
  • Granules India Unveils 'Breast Health Express' Mobile Unit
  • Granules India's Gagillapur Facility Completes US FDA Inspection with Six Observations
  • Granules India Limited receives ANDA approval for Glycopyrrolate Oral Solution
  • Granules India Ltd Q1 FY25 consolidated PAT higher at Rs. 134.64 crores
  • Granules India Ltd Q4 FY2024 consolidated profit rises to Rs. 129.64 crores

Latest Post

  • Mayank Cattle Food Ltd launches Mayank Vita H Liquid
  • Morepen Labs Q4 Net Profit Rises 69%
  • AXISCADES Wins Order from DRDO's R & DE for Mobile Mast System
  • Senco Gold Ltd delivers highest ever top-line in FY26
  • Apeejay Surrendra Park Hotels Reports Q4 and Full-Year FY26 Financial Results


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025